Oramed Pharma Raises $5 Million from Guangxi Wuzhou Zhongheng

Oramed Pharmaceuticals, an Israeli developer of novel oral delivery drugs, raised $5 million in a private placement with Guangxi Wuzhou Zhongheng Group. Oramed will use the proceeds for clinical trials of ORMD-0801, an oral insulin product, and development of its oral GLP-1 analog project, also for diabetes. Oramed expects Zhongheng to develop its oral drug products in China. More details.... Stock Symbols: (NSDQ: ORMP) (SHA: 600252) Share this with colleagues: // //